UroGen Pharma Ltd.
URGN
$47.11
$0.801.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 39.12% | 10.58% | 20.94% | 33.23% | -13.91% |
| Total Depreciation and Amortization | 2.45% | -3.98% | 6.26% | 7.21% | 19.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.69% | 73.73% | -27.00% | 41.62% | 9.49% |
| Change in Net Operating Assets | 18.31% | -76.28% | -14.92% | -383.36% | 302.63% |
| Cash from Operations | 27.16% | -18.24% | 9.33% | -6.14% | 5.23% |
| Capital Expenditure | -11.11% | -217.65% | 80.46% | 38.30% | -220.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.40% | -174.40% | -11.91% | 10.29% | 210.14% |
| Cash from Investing | 108.09% | -174.64% | -11.72% | 10.53% | 209.41% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -20.56% | 82.70% | -- | -- | -- |
| Issuance of Common Stock | 395.53% | -99.46% | 301.04% | 2,723.21% | 761.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | -99.23% | 108.21% | 278.58% | 2,694.59% | 770.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,754.13% | -103.86% | 896.46% | 76.63% | 83.63% |